Molecular Imaging in Oncology

Mol Img Intro - Tiny Spies

• Definition: Non-invasive visualization, characterization, and measurement of biological processes at molecular/cellular levels in vivo.
• Mechanism: Employs "tiny spies" (molecular probes, e.g., radiotracers) that target specific biological molecules or pathways.
  • These probes emit detectable signals, mapped by imaging devices.
• Core Principle: Focuses on function & physiology, offering insights beyond anatomical imaging (structure).

  ⭐ Molecular imaging visualizes cellular/subcellular processes, unlike anatomical imaging.

• Oncology Edge:
  • Early detection, often before anatomical changes manifest.
  • Precise tumor characterization & staging.
  • Guiding personalized treatment strategies.
  • Monitoring therapeutic response & early recurrence detection.

PET/CT Oncology - Sugar & Beyond

• $ ^{18}F-FDG $ (Fluorodeoxyglucose): The Workhorse

  • Mechanism: Glucose analog, ↑ glycolysis in cancer (Warburg effect).
  • Key metric: SUVmax (Standardized Uptake Value).
  • Applications: Staging, restaging, therapy response in lymphoma, lung, colorectal, melanoma, H&N, esophageal, breast.
  • Limitations: False positives (inflammation/infection), some low-grade/specific tumors (e.g., prostate).

• Beyond FDG: Specialized Tracers

  • Prostate Ca: $ ^{68}Ga-PSMA $, $ ^{18}F-PSMA $ (PSMA ligands); $ ^{11}C/^{18}F-Choline $.
  • NETs: $ ^{68}Ga-DOTATATE/NOC/TOC $ (Somatostatin receptor analogs).
  • Brain Tumors: $ ^{18}F-FET $ (amino acid tracer).
  • Hypoxia: $ ^{18}F-FMISO $.
  • Proliferation: $ ^{18}F-FLT $.

⭐ FDG-PET is crucial for staging and response assessment in lymphoma (Deauville score).

• Deauville Score (Lymphoma Response)
  • 5-point scale: Lesion $ ^{18}F-FDG $ uptake vs. mediastinum (M) & liver (L).
  • 📌 Scores 1-3 generally indicate Complete Metabolic Response (CMR).

SPECT & Theranostics - Scan & Strike

• SPECT (Single Photon Emission Computed Tomography)

  • Detects gamma rays from radiotracers (e.g., $ ^{99m}Tc-MDP $ (bone scans), $ ^{99m}Tc-MIBI $ (cardiac), $ ^{123}I $ (thyroid), $ ^{111}In-Octreotide $ (NETs)).
  • Uses: Bone scans, myocardial perfusion, brain imaging (dementia), tumor localization.
  • Pros: Cost-effective, accessible. Cons: Lower resolution than PET.

• Theranostics: "Scan & Strike" / Personalized Medicine

  • Pairs diagnostic imaging with targeted radionuclide therapy for the same molecular target.
  • 📌 "See what you treat, treat what you see."
  • Key Theranostic Pairs:
    • Thyroid Cancer: $ ^{131}I $ (scan & therapy).
    • NETs: $ ^{68}Ga-DOTATATE $ (scan) + $ ^{177}Lu-DOTATATE $ (therapy).
    • Prostate Cancer: $ ^{68}Ga-PSMA $ (scan) + $ ^{177}Lu-PSMA $ (therapy).

  ⭐ Theranostics combines diagnostic imaging with targeted radionuclide therapy using the same molecular target.

Clinical Applications - Cancer Spotting

• Detection & Characterization:
  • Identifies occult primary (e.g., CUP).
  • Differentiates benign vs. malignant lesions.
• Staging & Restaging:
  • Precise TNM staging (Nodal & Distant Metastases).
  • Detects recurrence, crucial for treatment plan.
• Biopsy Guidance: Targets metabolically active tumor sites.
• Key Cancers:
  • Lung: Solitary Pulmonary Nodule (SPN), staging.
  • Lymphoma: Initial staging.
  • Colorectal: Recurrence detection.
  • Melanoma: Staging.
  • Head & Neck: Staging, identifying unknown primary.

⭐ PET/CT significantly impacts management in ~30-40% of oncology cases by altering staging or treatment plan.

High‑Yield Points - ⚡ Biggest Takeaways

• FDG-PET/CT is key for staging, restaging, and response assessment in many cancers (lymphoma, lung).
• ¹⁸F-FDG uptake indicates high glucose metabolism in tumors (Warburg effect).
• ⁶⁸Ga-DOTATATE PET/CT is superior for neuroendocrine tumors (NETs) expressing somatostatin receptors.
• PSMA PET/CT is highly sensitive for prostate cancer staging and recurrence detection.
• Radioiodine (¹³¹I) is used for imaging and therapy of differentiated thyroid cancer.
• FDG-PET limitations: false positives (inflammation) and negatives (low-grade tumors, hyperglycemia).